Skip to main content

Table 1 Patient baseline demographic and clinical characteristics

From: Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer

Covariate Infants < 2 years n = 2 Children 2 to < 12 years n = 29 Adolescents 12 to < 18 years n = 38 Young adults ≥ 18 years n = 18
n (%) Median (min–max) n (%) Median (min–max) n (%) Median (min–max) n (%) Median (min–max)
Age, years 2 1 (0.6–1.5) 29 7 (2–11) 38 15 (12–17) 18 22 (18–29)
Body weight, kg 2 9.1 (8.7–9.5) 29 22.5 (12.0–74.4) 38 51.1 (28.2–105) 18 61.0 (46.2–154)
Albumin, g/L 2 33 (30–35) 28a 41 (23–46) 38 41 (29–49) 18 39 (27–47)
Tumor burden, mm 2 59 (35–83) 23b 55 (15–301) 28d 78 (11–208) 15e 120 (10–258)
Female 1 (50) 14 (48) 16 (42) 9 (50)
ADA positive 0 (0)a 5 (17)c 4 (11)e 2 (11)a
No. of tumor types present 2 1 29 12 38 15 18 10
Lansky/Karnofsky PS 2 90 (90–90) 29 100 (60–100) 38 90 (70–100) 18 95 (70–100)
  1. Abbreviations: ADA Anti-drug antibodies, PS Performance status
  2. an = 1, bn = 6, cn = 5, dn = 10, en = 3 missing covariates were imputed to the median value